EUCTR2007-002112-26-HU进行中（未招募）不适用
Open, single-arm phase-III study to investigate the percutaneous absorption of abafungin after topical dermal application of Abafungin cream 1.0 % (YORK Pharma GmbH) in 20 patients with tinea pedis interdigitalis
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 20
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •-caucasian male and female patients
- •-18 to 75 years of age
- •-presence of interdigital tinea pedis caused by dermatophytes on one or both feet, characterized by clinical evidence of involvement of more than one interdigital space and at least moderate erythema (at least score 2), and moderate scaling (at least score 2)
- •-a confirmatory microscopic demonstration of fungal elements
- •-the physical examination must be without other disease findings unless the investigator considers an abnormality to be irrelevant to the outcome of the study
- •-female patients of childbearing potential agree to undergo pregnancy tests and to use an appropriate method of contraception (i.e. oral contraceptive steroids, intrauterine device, barrier method)
- •-findings within the range of clinical acceptability in medical history and physical examination, and laboratory results within the normal ranges” for the relevant laboratory tests (unless the clinical investigator considers the deviation to be irrelevant for the purpose of the study). Normal ranges are included in Appendix III
- •-normal ECG and vital signs, or abnormalities which the clinical investigator does not consider a disqualification for participation in the study
- •-willingness to undergo a pre-study physical examination and pre- and post-study laboratory investigations
- •-ability to comprehend and willingness to sign both statements of informed consent (for screening and phase-related procedures).
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •received treatments like foot or shoe powders, pharmaceutical and cosmetic topicals (e.g. creams/gels, except for washing products) or topical anti-fungal therapy of the feet within 30 days before study entry, oral antifungal therapies within three months before study entry (8 months for oral terbinafine), systemic antibiotic or corticosteroid treatment, topical corticosteroids within 30 days before study entry, radiation therapy and/or anti-neoplastic agents within one year before study entry
- •receiving systemic therapy with cytotoxic or immunosuppressive drugs either concurrently or within 12 weeks before the baseline visit
- •receiving potassium permanganate drugs either concurrently or within 1 week before the baseline visit
- •use of antibacterial, antiviral or antihelminthic drugs concurrently or within 2 weeks before the baseline visit
- •evidence of drug or alcohol abuse
- •pregnancy or nursing
- •have symptoms of a clinically significant illness, or known laboratory value deviation, that may influence the safety of the patient, or the outcome of the study in the 30 days before and during the study
- •are known to be immunodeficient
- •have symptoms of a diabetic foot or neuropathies at foot/feet
- •have foot psoriasis, corn and/or callus involving any interdigital web spaces, atopic or contact dermatitis
- •widespread dermatophytoses, plantar / moccasin type tinea pedis, hyperkeratotic tinea pedis, tinea pedis or systemic fungal infection requiring systemic treatment, onychomycosis, tinea corporis, tinea cruris or tinea capitis, mucocutaneous candidiasis or bacterial skin infection
- •participation in another clinical trial involving pharmaceutical products in the 30 days preceding the study and during the study
- •known allergic reactions or known hypersensitivity to components of the study medications
- •in the opinion of the investigator or physician performing the initial examination the patient should not participate in the study, e. g. due to probable noncompliance or inability to answer questions or to assess tolerability of the study drug or to understand the study and give adequately informed consent.
- •Positive testing for HIV, HBsAg, or HCV.
- •Positive urine screen for drugs of abuse.
- •Do not tolerate vein puncture.
研究者
相似试验
招募中
1 期
A Phase 3b study to learn more about the safety and tolerability of ivosidenib in combination with azacitidine in adult patients newly diagnosed with IDH1m acute myeloid leukemia (AML) ineligible for intensive induction chemotherapyCTIS2022-501709-11-00Servier Affaires Medicales233
进行中（未招募）
不适用
Immunization of Children Between 8 Weeks and 2 Years of Age With a pneumococcal conjugate vaccineActive immunization against disease caused by Streptococcus pneumoniae in children from 8 weeks up to 2 years of age.MedDRA version: 17.1Level: PTClassification code 10061190Term: Haemophilus infectionSystem Organ Class: 10021881 - Infections and infestationsMedDRA version: 17.1Level: PTClassification code 10061353Term: Pneumococcal infectionSystem Organ Class: 10021881 - Infections and infestationsEUCTR2012-000254-64-Outside-EU/EEAGlaxoSmithKline Biologicals300
进行中（未招募）
不适用
Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and RotarixHealthy volunteers (Three dose primary vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b diseases and a two dose primary vaccination against rotavirus in healthy infants between 6 to 8 weeks of age at the time of the first vaccination.)MedDRA version: 18.0Level: LLTClassification code 10042197Term: Streptococcus pneumoniae septicaemiaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10042195Term: Streptococcus pneumoniae pneumoniaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10054642Term: Streptococcus pneumoniae septicemiaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10035648Term: Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia]System Organ Class: 100000004862EUCTR2015-001511-12-Outside-EU/EEAGlaxoSmithKline Biologicals230
进行中（未招募）
不适用
Primary vaccination course in children receiving the pneumococcal vaccine GSK 1024850A, Infanrix hexa and Rotarix.EUCTR2015-001510-10-Outside-EU/EEAGlaxoSmithKline Biologicals230
进行中（未招募）
不适用
Safety, reactogenicity and immunogenicity study of GSK Biologicals’ pneumococcal vaccine GSK1024850A, given either as a booster dose or as a 2-dose catch-up immunization in healthy Nigerian childreHealthy volunteers (for booster immunization of healthy children previously primed with 3 doses of pneumococcal conjugate vaccine [Pn-Pn group] or a two-dose catch-up immunization in unprimed children previously enrolled in the 10PN-PD-DIT-032 primary vaccination study [Zil-Pn group])MedDRA version: 18.0Level: LLTClassification code 10042197Term: Streptococcus pneumoniae septicaemiaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10042195Term: Streptococcus pneumoniae pneumoniaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10054642Term: Streptococcus pneumoniae septicemiaSystem Organ Class: 100000004862MedDRA version: 18.0Level: LLTClassification code 10035648Term: Pneumococcal pneumonia [Streptococcus pneumoniae pneumonia]System Organ Class: 100000004862EUCTR2012-000826-23-Outside-EU/EEAGlaxoSmithKline Biologicals107